Last €3.72 EUR
Change Today +0.021 / 0.57%
Volume 0.0
MED On Other Exchanges
As of 3:35 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

mediclin ag (MED) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/4/13 - €4.62
52 Week Low
10/16/14 - €3.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDICLIN AG (MED)

Related News

No related news articles were found.

mediclin ag (MED) Related Businessweek News

No Related Businessweek News Found

mediclin ag (MED) Details

MEDICLIN Aktiengesellschaft operates hospitals and provides services in the areas of neurosciences, psychological sciences, and orthopedics in Germany. The company’s Post-Acute segment offers services in the fields of subsequent nursing treatment and curative procedures. This segment’s subsequent nursing treatment includes various medical measures required to facilitate the healing process and return the patient to a functioning state after acute care treatment; and curative treatment comprises prophylactic measures against the occurrence or reoccurrence of illnesses. Its Acute segment encompasses medical offerings focusing on neurology and neurological early rehabilitation, as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. This segment also offers services in the areas of cardiology, oncology, and ENT; and provides acute outpatient services. The company’s Other activities segment offers full-time and short-term nursing care; and outpatient nursing care in the nursing care facilities. MEDICLIN Aktiengesellschaft operates 34 clinics, 7 nursing care facilities, and 11 medical care centers with a total capacity of approximately 8,100 beds in 11 German federal states. The company is headquartered in Offenburg, Germany.

6,405 Employees
Last Reported Date: 10/31/14

mediclin ag (MED) Top Compensated Officers

Chief Financial Officer and Member of the Man...
Total Annual Compensation: €324.7K
Compensation as of Fiscal Year 2013.

mediclin ag (MED) Key Developments

Mediclin AG Announces Board Appointments

Mediclin AG appointed Mrs. Irmtraut G-rkan and Rainer Laufs as members of the Supervisory Board representing the shareholders of the company. Mrs. Irmtraut G-rkan has been Business Director of Universit-tsklinikum Heidelberg since 2003. In addition to sector expertise, Mrs. G-rkan has operational experience and strategic competencies in line with what the healthcare market expects of its key personnel. Mrs. G-rkan was a member of the Advisory Board of MediClin AG for many years. Rainer Laufs gained most of his professional experience in the Shell group. His last position was Chairman of the Management Board of Deutsche Shell AG. Mrs. G-rkan and Mr. Laufs will succeed Dr. Daniel von Borries and Dr. Jochen Messemer, who have resigned from the Supervisory Board with effect of 4 September 2014.

Mediclin AG Announces Earnings Results for the Nine Months Ended Sep. 30, 2014; Provides Earnings Guidance for the Year 2014

Mediclin AG announced earnings results for the nine months ended Sep. 30, 2014. The company achieved group sales of EUR 402.8 million compared to EUR 389.7 million a year ago. Compared to the nine-month-period 2013 the group operating result improved by EUR 10.0 million from EUR 2.2 million to EUR 12.2 million and the result after tax attributable to shareholders of the company was EUR 8 million compared to loss of EUR 1.4 million a year ago. The business development of the first nine months 2014 leads to the expectation that the predicted sales targets of the group will be 3.0% for 2014. The 2014 earning targets of EUR 4 to 6 million for the group operating result will be slightly increased.

Mediclin AG Announces Earnings Results for the First Half of 2014; Provides Earnings Guidance for the Full Year of 2014

Mediclin AG announced earnings results for the first half of 2014. For the period, the company reported sales of EUR 266.7 million against EUR 257.4 million in the first half-year of 2014 thus being EUR 9.3 million or 3.6 % above the previous first half-year's value. Operating result improved by EUR 6.7 million from EUR 3.6 million to EUR 3.1 million compared to the first half-year of 2013. Result after tax attributable to shareholders was EUR 6.6 million from EUR 5.6 million to EUR 1.0 million. Net profit attributable to shareholders amounted to EUR 1 million compared with a loss of EUR 5.6 million in the prior-year period. Cash flow from operating activities was EUR 7.5 million against cash flow used in operating activities of EUR 2.6 million a year ago. Undiluted earnings per share were EUR 0.02 against LPS of EUR 0.12 a year ago. Sales and earnings improvements that are expected on the back of the measures already initiated, the management board assumes that the target margins for both the group and the segments will be reached in 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MED:GR €3.72 EUR +0.021

MED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MED.
View Industry Companies

Industry Analysis


Industry Average

Valuation MED Industry Range
Price/Earnings 25.5x
Price/Sales 0.3x
Price/Book 1.1x
Price/Cash Flow 7.1x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICLIN AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at